Which psychotropic medications induce hepatotoxicity?

General Hospital Psychiatry

Volumn 34, Issue 1, 2012, Pages 53-61

  Sedky, Karim ^a   Nazir, Racha ^b   Joshi, Aditya ^b   Kaur, Gagandeep ^c   Lippmann, Steven ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Hepatic dysfunction; Hepatotoxic drugs; Hepatotoxicity; Liver failure; Medication and liver toxicity; Psychiatric drugs; Psychotropic medicines

Indexed keywords

AMFEBUTAMONE; AMINEPTINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESVENLAFAXINE; DRUGS USED IN THE TREATMENT OF ADDICTION; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HERBACEOUS AGENT; HYDROXYZINE; MIRTAZAPINE; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABNORMAL LABORATORY RESULT; ACUTE HEPATITIS; ALCOHOLISM; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATTY LIVER; HEPATOBILIARY DISEASE; HUMAN; IDIOSYNCRATIC LIVER DAMAGE; INCIDENCE; JAUNDICE; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NONHUMAN; OBSTRUCTIVE JAUNDICE; PRESCRIPTION; PRURITUS; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW;

DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS;

EID: 84855357195     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2011.10.007     Document Type: Article

References (148)

1. Pugh A.J., Barve A.J., Falkner K., Patel M., McClain C.J. Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis 2009, 13(2):277-294.
2. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 2003, 349(5):474-485.
3. Meier Y., Cavallaro M., Roos M., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005, 61:135-143.
4. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137(12):947-954.
5. Sass D.A., Shakil A.O. Fulminant hepatic failure. Liver Transpl 2005, 11(6):594-605.
6. Nathwani R.A., Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006, 10(2):207-217.
7. Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005, 42:481-489.
8. Capella D., Bruguera M., Figueras A., Laporte J. Fluoxetine-induced hepatitis: why is postmarketing surveillance needed?. Eur J Clin Pharmacol 1999, 55:545-546.
9. Bellmann R., Feistritzer C., Zoller H., Graziadei I.W., Schwaighofer H., Propst A., et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. ASAIO J 2004, 50(4):387-391.
10. Johnston D.E., Wheeler D.E. Chronic hepatitis related to use of fluoxetine. Am J Gastroenterol 1997, 92(7):1225-1226.
11. Pompili M., Tittoto P., Mascianà R., Gasbarrini G., Rapaccini G.L. Acute hepatitis associated with use of paroxetine. Intern Emerg Med 2008, 3(3):275-277.
12. Persky S., Reinus J.F. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci 2003, 48(5):939-944.
13. Tabak F., Gunduz F., Tahan V., Tabak O., Ozaras R. Sertraline hepatotoxicity: report of a case and review of the literature. Dig Dis Sci 2009, 54(7):1589-1591.
14. Solomons K., Gooch S., Wong A. Toxicity with selective serotonin reuptake inhibitors. Am J Psychiatry 2005, 162:1225.
15. Neumann H., Csepregi A., Evert M., Malfertheiner P. Drug-induced liver disease related to citalopram. J Clin Psychopharmacol 2008, 28(2):254-255.
16. Lopez-Torres E., Lucena M.I., Seoane J., Verge C., Andrade R.J. Hepatotoxicity related to citalopram. Am J Psychiatry 2004, 161:923-924.
17. Gleason O.C., Yates W.R., Philipsen M.A., Isbell M.D., Pollock B.G. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004, 45(1):29-33.
18. Fredricson Overø K., Svendsen O. Hepatotoxicity of citalopram in rats and first-pass metabolism. Arch Toxicol Suppl 1978, 1:177-180.
19. Humayun F., Shehab T.M., Tworek J.A., Fontana R.J. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: case report. J Med Case Rep 2007, 1:88.
20. Khoo A.L., Tham L.S., Lee K.H., Lim G.K. Acute liver failure with concurrent bupropion and carbimazole therapy. Ann Pharmacother 2003, 37(2):220-223.
21. DeSanty K.P., Amabile C.M. Antidepressant-induced liver injury. Ann Pharmacother 2007, 41(7):1201-1211.
22. Rosack J. FDA orders liver warning on nefazodone labels. Psych News 2002, 37(3):19.
23. Carvajal García-Pando A., García del Pozo J., Sánchez A.S., Velasco M.A., Rueda de Castro A.M., Lucena M.I. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002, 63(2):135-137.
24. Aranda-Michel J., Koehler A., Bejarano P.A., Poulos J.E., et al. Nefazodone-induced liver failure: report of three cases. Ann Intern Med 1999, 130:285-288.
25. Dykens J.A., Jamieson J.D., Marroquin L.D., et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008, 103(2):335-345.
26. Phillips B.B. Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms. Ann Pharmacother 2006, 40(2):323-327.
27. Shaw M.W., Sheard J.D. Fatal venlafaxine overdose with acinar zone 3 liver cell necrosis. Am J Forensic Med Pathol 2005, 26(4):367-368.
28. Lourenco M.T., Kennedy S.H. Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2009, 5:127-136.
29. Wernicke J., Pangallo B., Wang F., et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf 2008, 3(2):132-142.
30. Wernicke J., Acharya N., Strombom I., et al. Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events. Curr Drug Saf 2008, 3(2):143-153.
31. McIntyre R.S., Panjwani Z.D., Nguyen H.T., Woldeyohannes H.O., Alsuwaidan M., Soczynska J.K., et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008, 4(3):281-285.
32. Wohlreich M.M., Acharya N., Strombom I., et al. Answers to the most common questions about the hepatic safety profile of duloxetine. Postgrad Med 2008, 120(2):111-118.
33. Fernandes N.F., Martin R.R., Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol 2000, 95(2):532-535.
34. Beck P.L., Bridges R.J., Demetrick D.J., Kelly J.K., Lee S.S. Chronic active hepatitis associated with trazodone therapy. Ann Intern Med 1993, 118(10):791-792.
35. Adetunji B., Basil B., Mathews M., Osinowo Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes. Ann Pharmacother 2007, 41(2):359.
36. Hui C.K., Yuen M.F., Wong W.M., Lam S.K., Lai C.L. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol 2002, 35(3):270-271.
37. Lucena M.I., Carvajal A., Andrade R.J., Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2003, 2(3):249-262.
38. Larrey D., Rueff B., Pessayre D., et al. Cross hepatotoxicity between tricyclic antidepressants. Gut 1986, 27:726-727.
39. Horst D.A., Grace N.D., LeCompte P.M. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology 1980, 79(3):550-554.
40. Richards D.J. Allergy to iprindole (Prondole) with hepatotoxicity. Br Med J 1970, 4(5733):495.
41. Clein L.J. Allergy to iprindole (Prondole) with hepatotoxicity. Br J Med 1970, 4(5733):494-495.
42. Remy A.J., Larrey D., Pageaux G.P., Ribstein J., Ramos J., Michel H. Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur J Gastroenterol Hepatol 1995, 7(4):373-376.
43. LeBricquir Y., Larrey D., Blanc P., Pageaux G.P., Michel H. Tianeptine - an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol 1994, 21(5):771-773.
44. Kuhn W.F., Jones D.R., Lippmann S.B., et al. Clinical and pharmacological considerations in elimination of tricyclic antidepressants and metabolites after overdose. J Clin Psychopharmacol 1984, 4(3):158-160.
45. Braun J.S., Geiger R., Wehner H., Schaffer S., Berger M. Hepatitis caused by antidepressive therapy with maprotiline and opipramol. Pharmacopsychiatry 1998, 31(4):152-155.
46. Gollini C., Dallari R., Cervi F., Mengoli M. Iproniazid-induced acute hepatitis. Recenti Prog Med 1992, 83(6):354-355.
47. Bonkovsky H.L., Blanchette P.L., Schned A.R. Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material. Am J Med 1986, 80(4):689-692.
48. Daneshmend T.K., Scott G.L., Bradfield J.W. Angiosarcoma of liver associated with phenelzine. Br J Med 1979, 1(6179):1679.
49. Zimmerman H.J., Ishak K.G. The hepatic injury of monoamine oxidase inhibitors. J Clin Psychopharmacol 1987, 7(4):211-213.
50. Anttila M., Sotaniemi E.A., Pelkonen O., Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharm Ther 2005, 77(1):54-62.
51. Atasoy N., Erdogan A., Yalug I., et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(6):1255-1260.
52. Dumortier G., Cabaret W., Stamatiadis L., et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002, 28(6):542-551.
53. Hansen T.E., Casey D.E., Hoffman W.F. Neuroleptic intolerance. Schizophr Bull 1997, 23(4):567-582.
54. Selim K., Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology 1999, 29(5):1347-1351.
55. Gaertner I., Altendorf K., Batra A., Gaertner H.J. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol 2001, 21(2):215-222.
56. Hummer M., Kurz M., Kurzthaler I., Oberbauer H., Miller C., Fleischhacker W.W. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997, 17(4):314-317.
57. Fuller C.M., Yassinger S., Donlon P., Imperato T.J., Ruebner B. Haloperidol-induced liver disease. West J Med 1977, 127(6):515-518.
58. Macfarlane B., Davies S., Mannan K., Sarsam R., Pariente D., Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997, 112(5):1707-1709.
59. Kelly D.L., Conley R.R., Richardson C.M., Tamminga C.A., Carpenter W.T. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 2003, 15(3-4):181-186.
60. Erdogan A., Kocabasoglu N., Yalug I., Ozbay G., Senturk H. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 2004, 34(1):83-89.
61. Larsen J.T., Clemensen S.V., Klitgaard N.A., Nielsen B., Brosen K. Clozapine-induced toxic hepatitis. Ugeskr Laeger 2001, 163(14):2013-2014.
62. Panagiotis B. Grand mal seizures with liver toxicity in a case of clozapine treatment. J Neuropsychiatry Clin Neurosci 1999, 11(1):117-118.
63. Erdogan A., Atasoy N., Akkurt H., et al. Risperidone and liver function tests in children and adolescents: a short-term prospective study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(3):849-857.
64. Holtmann M., Kopf D., Mayer M., Bechtinger E., Schmidt M.H. Risperidone-associated steatohepatitis and excessive weight-gain. Pharmacopsychiatry 2003, 36:206-207.
65. Kumra S., Herion D., Jacobsen L.K., Briguglia C., Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997, 36(5):701-705.
66. Wright T.M., Vandenberg A.M. Risperidone- and quetiapine-induced cholestasis. Ann Pharmacother 2007, 41(9):1518-1523.
67. Tello F.L., Prats C.H., Ros N.B., et al. Acute cholestatic hepatitis probably associated with risperidone. Int J Psychiatry Med 2005, 35(2):199-205.
68. Esposito D., Brocvielle H., Becquemont L., et al. Risperidone-induced immunoallergic hepatitis. Am J Psychiatry 2005, 162:1984.
69. Halici Z., Keles O.N., Unal D., et al. Chronically administered risperidone did not change the number of hepatocytes in rats: a stereological and histopathological study. Basic Clin Pharmacol Toxicol 2008, 102(5):426-432.
70. Vermeir M., Naessens I., Remmerie B., et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008, 36(4):769-779.
71. Jadallah K.A., Limauro D.L., Colatrella A.M. Acute hepatocellular-cholestatic liver injury after olanzapine therapy. Ann Intern Med 2003, 138(4):357-358.
72. Kryzhanovskaya L., Schulz S.C., McDougle C., et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009, 48(1):60-70.
73. Kolpe M., Ravasia S. Effect of olanzapine on the liver transaminases. Can J Psych 2003, 48(3):210.
74. Ozcanli T., Erdogan A., Ozdemir S., et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine-induced hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(6):1163-1166.
75. Pae C.U., Lim H.K., Kim T.S., et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol 2005, 20(3):173-176.
76. Odaci E., Bilen H., Hacimuftuoglu A., Keles O.N., Can I., Bilici M. Long-term treatments with low- and high dose olanzapine change hepatocyte numbers in rats. A stereological and histopathological study. Arch Med Res 2009, 40(3):139-145.
77. Shpaner A., Li W., Ankoma-Sey V., Botero R.C. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008, 20(11):1106-1109.
78. El Hajj I., Sharara A.I., Rockey D.C. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol 2004, 16(12):1415-1418.
79. Lin S.N., Chang Y., Moody D.E., Foltz R.L. A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol 2004, 28(6):443-448.
80. Thyrum P.T., Wong Y.W., Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24(4):521-533.
81. Everson G., Lasseter K.C., Anderson K.E., et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol 2000, 49(Suppl 1):21S-26S.
82. Abilify package insert Bristol-Myers Squibb Co, Princeton, NJ, USA Last accessed on May 19, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21436slr006_abilify_lbl.pdf.
83. Mallikaarjun S., Shoaf S.E., Boulton D.W., Bramer S.L. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet 2008, 47(8):533-542.
84. Tegretol package insert Novartis Pharmaceuticals Co, East Hanover, NJ, USA Last accessed on May 19, 2011. http://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf.
85. Adams E.N., Marks A., Lizer M.H. Carbamazepine-induced hyperammonemia. Am J Health Syst Pharm 2009, 66(16):1468-1470.
86. Fernando S.L., Henderson C.J., O'Connor K.S. Drug-induced hypersensitivity syndrome with superficial granulomatous dermatitis-a novel finding. Am J Dermatopathol 2009, 31:611-613.
87. Ganeva M., Gancheva T., Lazarova R., et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008, 47(8):853-860.
88. Frey B., Braegger C.P., Ghelfi D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann Pharmacother 2002, 36(4):644-647.
89. Gaida-Hommernick B., Rieck K., Runge U. Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2001, 42(6):793-795.
90. Lautz T.B., Finegold M.J., Chin A.C., Superina R.A. Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy. J Pediatr Surg 2008, 43(4):751-754.
91. Bosdure E., Cano A., Roquelaure B., et al. Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure. Arch Pediatr 2004, 11(9):1073-1077.
92. Luef G., Rauchenzauner M., Waldmann M., et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009, 86(1):42-47.
93. Huang Y.L., Hong H.S., Wang Z.W., Kuo T.T. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol 2003, 49(2):316-319.
94. Bryant A.E., Dreifuss F.E. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996, 46(2):465-469.
95. Lheureux P.E., Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol 2009, 47(2):101-111.
96. Carol A. Valproic acid-induced hyperammonemia in a patient with schizoaffective disorder. J Pharm Pract 2007, 20(1):82-92.
97. Krähenbühl S., Brandner S., Kleinle S., Liechti S., Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000, 20(4):346-348.
98. Seki A., Inoue T., Maegaki Y., et al. Polycystic ovary syndrome and hepatocellular adenoma related to long-term use of sodium valproate in a young woman. No To Hattatsu 2006, 38(3):205-208.
99. Sato K., Ueda Y., Ueno K., Okamoto K., Lizuka H., Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 2005, 447(6):996-999.
100. Felker B.L., Sloan K.L., Dominitz J.A., Barnes R.F. The safety of valproic acid use for patients with hepatitis C infection. Am J Psychiatry 2003, 160(1):174-178.
101. Moeller K.E., Wei L., Jewell A.D., Carver L.A. Acute hepatotoxicity associated with lamotrigine. Am J Psychiatry 2008, 165(4):539-540.
102. Amante M.F., Filippini A.V., Cejas N., Lendoire J., Imventarza O., Parisi C. DRESS syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol 2009, 8(1):75-77.
103. Su-Yin A.N., Tai W.W., Olson K.R. Lamotrigine-associated reversible severe hepatitis: a case report. J Med Toxicol 2008, 4(4):258-260.
104. Bumb A., Diederich N., Beyenburg S. Adding topiramate to valproate therapy may cause reversible hepatic failure. Epileptic Disord 2003, 5(3):157-159.
105. Bjøro K., Gjerstad L., Bentdal O., Osnes S., Schrumpf E. Topiramate and fulminant liver failure. Lancet 1998, 352(9134):1119.
106. Huang J., Ren R.N., Chen X.M., Ye L.Y. An experimental study on hepatotoxicity of topiramate in young rats. Zhongguo Dang Dai Er Ke Za Zhi 2007, 9(1):54-58.
107. Richardson C.E., Williams D.W., Kingham J.G. Gabapentin induced cholestasis. Br Med J 2002, 325(7365):635.
108. Lasso-de-la-Vega M.C., Zapater P., Such J., Perez-Mateo M., Horga J.F. Gabapentin-associated hepatotoxicity. Am J Gastroenterol 2001, 96(12):3460-3462.
109. Lyrica package insert Pfizer pharmaceuticals LLC, Vega Baja, PR, USA Last accessed on May 19, 2011. http://www.pfizer.com/files/products/uspi_lyrica.pdf.
110. Einarsdottir S., Björnsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol 2008, 20(10):1049.
111. Kosson H., Chou J.C. Abnormal liver function tests associated with lithium treatment. J Clin Psychopharmacol 1992, 12(3):217-218.
112. Hazelwood R.E. Ascites: a side effect of lithium treatment?. Am J Psychiatry 1981, 138:257.
113. Warick H.L. Lithium poisoning: report of a case with neurologic, cardiac and hepatic sequelae. West J Med 1979, 130:259-263.
114. Cohen L.S., Cohen D.E. Lithium-induced hyperbilirubinemia in an adolescent. J Clin Psychopharmacol 1991, 11:274.
115. Walter A.J. Possible hepatotoxic effect of methadone. Can Med Assoc J 1969, 100(5):265-266.
116. Jover R., Ponsoda X., Gómez-Lechón M.J., Castell J.V. Potentiation of heroin and methadone hepatotoxicity by ethanol: an in vitro study using cultured human hepatocytes. Xenobiotica 1992, 22(4):471-478.
117. Kanchana T.P., Kaul V., Manzarbeitia C., et al. Liver transplantation for patients on methadone maintenance. Liver Transpl 2002, 8(9):778-782.
118. Berson A., Gervais A., Cazals D., et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001, 34(2):346-350.
119. Sax D.S., Kornetsky C., Kim A. Lack of hepatoxicity with naltrexone treatment. J Clin Pharmacol 1994, 34:898-901.
120. Dilts S.L., Dilts S.L. Assessing liver function before initiating disulfiram therapy. Am J Psychiatry 1996, 153(11):1504-1505.
121. Mendenhall M. Disulfiram-induced fulminant hepatic failure in an active duty soldier. Mil Med 2004, 169(8):671-672.
122. Marotta P.J., Roberts E.A. Pemoline hepatotoxicity in children. J Pediatr 1998, 132(5):894-897.
123. Safer D.J., Zito J.M., Gardner J.E. Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001, 40(6):622-629.
124. Rosh J.R., Dellert S.F., Narkewicz M., Birnbaum A., Whitington G. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis. Pediatrics 1998, 101(5):921-923.
125. Sterling M.J., Kane M., Grace N.D. Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 1996, 91(10):2233-2234.
126. Adcock K.G., MacElroy D.E., Wolford E.T., Farrington E.A. Pemoline therapy resulting in liver transplantation. Ann Pharmacother 1998, 32(4):422-425.
127. Elitsur Y. Pemoline (Cylert)-induced hepatotoxicity. J Pediatr Gastroenterol Nutr 1990, 11(1):143-144.
128. Pratt D.S., Dubois R.S. Hepatotoxicity due to pemoline (Cylert): a report of two cases. J Pediatr Gastroenterol Nutr 1990, 10(2):239-241.
129. Food and Drug Administration Web site Last accessed on May 19, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126461.htm.
130. Strattera package insert Eli Lilly and Co, Indianapolis, IN, USA Last accessed on May 19, 2011. http://pi.lilly.com/us/strattera-pi.pdf.
131. Bangs M.E., Jin L., Zhang S., et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008, 31(4):345-354.
132. Stojanovski S.D., Casavant M.J., Mousa H.M., Baker P., Nahata M.C. Atomoxetine-induced hepatitis in a child. Clin Toxicol 2007, 45(1):51-55.
133. Gracon S.I., Knapp M.J., Berghoff W.G., et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998, 12(2):93-101.
134. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271(13):992-998.
135. Blackard W.G., Sood G.K., Crowe D.R., Fallon M.B. Tacrine. A cause of fatal hepatotoxicity?. J Clin Gastroenterol 1998, 26(1):57-59.
136. Ames D.J., Bhathal P.S., Davies B.M., Fraser J.R., Gibson P.R., Roberts S. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Aust N Z J Med 1990, 20(2):193-195.
137. Verrico M.M., Nace D.A., Towers A.L. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc 2000, 48(12):1659-1663.
138. Dierckx R.I., Vandewoude M.F. Donepezil-related toxic hepatitis. Acta Clin Belg 2008, 63(5):339-342.
139. Mumoli N., Carmignani G., Luschi R., Chiavistelli P. Hepatitis with cholestasis caused by rivastigmine transdermal patch. Am J Gastroenterol 2009, 104(11):2859-2860.
140. Ferrara N., Corbi G., Capuano A., Fillipelli A., Rossi F. Memantine-induced hepatitis with cholestasis in a very elderly patient. Ann Intern Med 2008, 148(8):631-632.
141. Scott L.J., Goa K.L. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000, 60(5):1095-1122.
142. Andrade R.J., Lucena M.I., Aguilar J., et al. Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Dig Dis Sci 2000, 45(7):1400-1404.
143. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008, 20(12):1182-1193.
144. Humberston C.L., Akhtar J., Krenzelok E.P. J Toxicol Clin Toxicol 2003, 41(2):109-113.
145. Gow P.J., Connelly N.J., Hill R.L., Crowley P., Angus P.W. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003, 178:442-443.
146. MacGregor F.B., Abernethy V.E., Dahabra S., Cobden I., Hayes P.C. Hepatotoxicity of herbal remedies. BMJ 1989, 299:1156-1157.
147. Maddrey W.C. Drug-induced hepatotoxicity. J Clin Gastroenterol 2005, 39(4 Suppl 2):S83-S89.
148. Senior J.R. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?. Clin Pharm Ther 2009, 85(3):331-334.